[en] Adequate infection prophylaxis and empirical antibiotic therapy are of critical importance after hematopoietic stem cell transplantation (HSCT). We examined the evolution of bacterial susceptibility to antibiotics in 492 patients (198 allografts and 294 autografts) transplanted between 1982 and 1999 and evaluated whether ciprofloxacin prophylaxis and an empirical antibiotic regimen (glycopeptide + third-generation cephalosporin) were still valid. We collected all susceptibility tests performed during the initial hospitalization on blood cultures as well as routine surveillance cultures and analyzed susceptibility to ciprofloxacin and to major antibiotics used in our unit. Gram-positive cocci rapidly became resistant to ciprofloxacin (susceptibility around 70% in 1990 to less than 20% in 1998) but sensitivity to glycopeptides remained unaltered. There was a rapid decline in the number of patients colonized with Gram-negative bacilli in the early years of ciprofloxacin prophylaxis. However, susceptibility to ciprofloxacin fell sharply from around 90% in 1990 to around 30% in 1999. In parallel, susceptibility to ceftazidime also decreased to less than 80% in recent years. Piperacillin (+/- tazobactam) did not show any variation over time and its efficacy remained too low (about 60%). Imipenem as well as recently introduced cefepim and meropenem showed stable and excellent profiles (>90% susceptibility). In conclusion: (1) quinolone prophylaxis has now lost most of its value; (2) the choice of a third-generation cephalosporin for empirical antibiotic therapy may no longer be the best because of the emergence of Gram-negative strains resistant to beta-lactamases, such as Enterobacter sp. More appropriate regimens of empirical antibiotic therapy in HSCT recipients may be based on the use of a carbapenem or fourth-generation cephalosporin.
Disciplines :
Hematology
Author, co-author :
Frere, Pascale ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Hermanne, J.-P.
Debouge, M.-H.
Fillet, Georges ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Beguin, Yves ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Language :
English
Title :
Changing pattern of bacterial susceptibility to antibiotics in hematopoietic stem cell transplant recipients.
Bosi A., Laszlo D., Bacci S. (1999) An open evaluation of triple antibiotic therapy including vancomycin for febrile bone marrow transplant recipients with severe neutropenia. J. Chemother 11:287-292.
Hugues W.T., Armstrong D., Bodey G.P. (1997) 1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin. Infect. Dis 25:551-573.
Delarive P., Baumgartner J.D., Glauser M.P., Cometta A. (2000) Evaluation of antibiotic prophylaxis in neutropenic patients with hematologic malignancies. Schweiz Med Wochenschr 130:1837-1844.
Kern W.V., Beyer J., Bohme A. (2000) Prophylaxis of infection in neutropenic patients. Guidelines of the working party on infections in hematology and oncology. Dtsch Med. Wocheschr 125:1582-1588.
Cruciani M. (2000) Antibacterial prophylaxis. Int. J. Antimicrob. Agents 16:123-125.
Yeh S.P., Hsueh E.J., Yu M.S. (1999) Oral ciprofloxacin as antibacterial prophylaxis after allogeneic bone marrow transplantation: A reappraisal. Bone Marrow Transplant 24:1207-1211.
Cometta A., Calandra T., Gaya H. (1996) Monotherapy with meropenem versus combination therapy with ceftazidim plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother , International antimicrobial therapy co-operative group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell' Adulto Infection Program; 40:1108-1115.
Gribble M.J., Chow A.W., Naiman S.C. (1983) Prospective randomized trial of piperacillin monotherapy versus carboxypenicillin-amynoglycoside combination regimens in the empirical treatment of serious bacterial infections. Antimicrob Agents Chemother 24:388-393.
Erjavec Z., de Vries-Hospers H.G., Laseur M. (2000) A prospective, randomized, double-blinded, placebo-controlled trial of empirical teicoplanin in febrile neutropenia with persistent fever after imipenem monotherapy. J. Antimicrob. Chemother 45:843-849.
Hoffken G., Pasold R., Pfluger K.H. (1999) An open, randomized, multicentre study comparing the use of low-dose ceftazidim or cefotaxime, both in combination with netilmicin, in febrile neutropenic patients. J. Antimicrob. Chemother , German Multicentre Study Group; 44:367-376.
Bergogne-Bérézin E. (1998) Pression de sélection et résistance bactérienne à l'hôpital. Presse Med 27:42-46.
Brun-Buisson C. (1999) Exposition aux antibiotiques et sélection de résistance: Données cliniques. Réanim Urgences 8:5s-11s.
Saurina G., Quale J.M., Manikal V.M. (2000) Antimicrobial resistance in Enterobacteriaceae in Brooklyn NY: Epidemiology and relation to antibiotic usage patterns. J. Antimicrob. Chemother 45:895-898.
Gulay Z., Thomson C.J., Yulug N., Amyes S.G. (2000) High prevalence of extended spectrum beta-lactamase production among Klebsiella pneumoniae strains isolated at a University Hospital in Turkey. J. Chemother 12:145-152.
Jacobson K.L., Cohen S.H., Inciardi J.F. (1995) The relationship between antecedent antibiotic use and resistance to extended-spectrum cephalosporins in group I β-lactamase-producing organisms. Clin. Infect. Dis 21:1107-1113.
Livermore D.M. (2000) Epidemiology of antibiotic resistance. Intensive Care Med 26:S14-S21.
Jones R.N., Jenkins S.G., Hoban D.J. (2000) In vitro efficacy of six cephalosporins tested against Enterobacteriaceae isolated at 38 North American medical centres participating in the SENTRY Antimicrobial Surveillance Program, 1997-1998. Int. J. Antimicrob. Agents 15:111-118.
McAlister T., George N., Faoagali J., Bell J. (1999) Isolation of beta-lactamase positive vancomycin resistant Enterococcus faecalis; first case in Australia. Commun. Dis. Intell 23:237-239.
Lai K.K., Kelley A.L., Melvin Z.S. (1998) Failure to eradicate vancomycin-resistant enterococci in a university hospital and the cost of barrier precautions. Infect. Control Hosp. Epidemiol 19:647-652.
Lundstrom T.S., Sobel J.D. (2000) Antibiotics for gram-positive bacterial infections. Vancomycin, teicoplanin, quinupristin/dalfopristin, and linezolid. Infect. Dis. Clin. North. Am 14:463-474.
Murray B.E. (2000) Problems and perils of vancomycin resistant enterococci. Braz J. Infect. Dis 4:9-14.
Jones R.N. (2000) Perspectives on the development of new antimicrobial agents for resistant gram-positive pathogens. Braz. J. Infect. Dis 4:1-8.
Lopez-Lozano J.M., Monnet D.L., Yague A. (2000) Modelling and forecasting antimicrobial resistance and its dynamic relationship to antimicrobial use: A time series analysis. Int. J. Antimicrob. Agents 14:21-31.
Pechère J.C. (1999) Sélection de résistance sous la pression des nouveaux antibiotiques. Réanim Urgences 8:22s-26s.
Mebis J., Goossens H., Bruyneel P. (1998) Decreasing antibiotic resistance of Enterobacteriaceae by introducing a new antibiotic combination therapy for neutropenic fever patients. Leukemia 12:1627-1629.